Salute e Benessere

Jazz Pharmaceuticals Promotes Samantha Pearce to Chief Commercial Officer

Ms. Pearce joined Jazz as SVP, Europe and International, in 2020, and brings more than 30 years of commercial experience in the pharmaceutical industry. Since joining Jazz, she has instilled a commitment to a high-performance culture, growing Jazz's commercial brands and harnessing the potential of Jazz's European and International business to provide transformative medicines for patients in more than 50 countries. In her role as Chief Commercial Officer, she will be responsible for strategy and…
PR Newswire
09/07/2024

uniQure Announces Positive Interim Data Update Demonstrating Slowing of Disease…

~ Achieved statistically significant, dose-dependent, and durable evidence of potential therapeutic benefit; Patients receiving high-dose AMT-130 showed 80% slowing of disease progression in the composite Unified Huntington's Disease Rating Scale (cUHDRS) at 24 months compared to a propensity score-weighted external control ~ ~ Achieved statistically significant lowering of CSF neurofilament light protein (NfL) compared to baseline at 24 months in patients treated with AMT-130; Mean CSF...
Nasdaq GlobeNewswire
09/07/2024

Tilray Medical Announces Scientific Study on Medical Cannabis for Patients Over…

Older Patients Represent a Rapidly Growing Subset for Therapeutic Medical Cannabis Use for Pain, Sleep, Quality of Life and Co-Medication Medical Cannabis for Patients Over Age 50: A Multi-Site, Prospective Study of Patterns of Use and Health Outcomes.The Medical Cannabis in Older Patients Study(“MCOPS”) is a multi-site, prospective, observational study examining the real-world impact of medical use on patients over the age of 50 and under the guidance of a healthcare provider...
Nasdaq GlobeNewswire
09/07/2024

Gryphon Investors-Backed Vetnique Labs to Acquire U.K. Maker of YuMOVE

YuMOVE is the U.K.'s number one joint mobility supplement for dogs and cats and also offers supplements that support digestive health, anxiety, dermatological and dental needs. Based in Hertfordshire, U.K., and founded two decades ago by Dr. John Howie DL and John Davies, YuMOVE aims to provide pets and their owners with scientifically supported supplements to manage chronic health conditions. It is also a certified B Corporation, a distinction achieved based on its high standards in ESG…
PR Newswire
09/07/2024

STALICLA appoints Dr. Purnanand Sarma, PhD, as Chair of the Board of Directors

Press ReleaseDr. Sarma brings exceptional expertise in all facets of the pharmaceutical and biotechnology business, from scaling platforms to developing therapeuticsGeneva, Switzerland – July 9, 2024– STALICLA SA, a Swiss neuro precision biotech company dedicated to developing precision medicine-based treatments for neurodevelopmental and neuropsychiatric disorders, such as autism spectrum disorder, announced today the appointment of Dr. Purnanand Sarma, PhD, as Chair of its Board...
Nasdaq GlobeNewswire
09/07/2024

Global Sacral Nerve Stimulation Market Size to worth $634.1 million by 2030…

Market Dynamics: Market Dynamics : The global sacral nerve stimulation market is witnessing significant growth due to increasing prevalence of overactive bladder and urge incontinence globally. According to the National Association for Continence, over 25 million Americans experience overactive bladder which is a progressive disease and more than 50% of the Americans between ages of 40 to 60 years are affected by overactive bladder. Further, rise in geriatric population and surge in obesity...
PR Newswire
09/07/2024

Global Workout Supplements Market Size to worth $36.38 billion by 2030, growing…

Market Dynamics: Market Dynamics : The global workout supplements market is witnessing significant growth owing to rising awareness about health and fitness among consumers. Growing consumption of protein supplements to build muscles and pre-workout supplements to boost energy levels is driving the market growth. Additionally, easy availability of supplements through online distribution channels and celebrity endorsements promoting the usage of supplements is further augmenting the market...
PR Newswire
09/07/2024

iOnctura announces expansion of roginolisib clinical trial program to NSCLC

Emerging clinical and translational biomarker data supports the hypothesis that combining roginolisib with a programmed death receptor-1 (PD-1) targeting agent, with or without docetaxel, may prevent or reverse drug resistance in NSCLC and may show synergistic anti-tumor immune activity without significant addition of toxicity3. Emerging clinical and translational biomarker data supports the hypothesis that combining roginolisib with a programmed death receptor-1 (PD-1) targeting agent, with…
PR Newswire
09/07/2024

Curve Therapeutics strengthens Leadership Team with appointment of experienced…

Simon Kerry, Chief Executive Officer of Curve Therapeutics, commented: "Simon brings extensive financial experience at the leadership level from multiple clinical stage biotech companies. His appointment comes at a pivotal time as we look to expand our team, advance our proprietary Microcycle® discovery platform, and progress our pipeline of potential first-in-class assets." Simon Kerry, Chief Executive Officer of Curve Therapeutics, commented: "Simon brings extensive financial…
PR Newswire
09/07/2024

Bruin Biometrics Announces PIPPA, The Only Medical Pressure Injury Technology To…

PIPPA is designed to integrate seamlessly with existing Electronic Medical Records, providing real-time data and analytics to healthcare providers. It automates the production of the SPIPP checklist, developed by NPIAP, ensuring high fidelity data collection and ease of use. This integration supports consistent and comprehensive application of the SPIPP checklist, helping to reduce the incidence of HAPIs and improve patient care. PIPPA is designed to integrate seamlessly with existing...
PR Newswire
09/07/2024

Indivior Provides Business Update; Conference Call at 8:00 AM U.S. EDT

Comment by Mark Crossley, CEO of Indivior PLC"Despite positive early performance trends at the start of the second quarter, SUBLOCADE net revenue (NR) has continued to be impacted more than we expected by a combination of transitory factors, primarily the elimination of COVID emergency measures related to automatic Medicaid coverage renewals. Furthermore, as we look to the second half of the year, the U.S. government has extended renewal allowances for certain States which will further…
PR Newswire
09/07/2024

SciRhom Secures EUR 63 Million Series A Financing Round to Accelerate…

The upsized and oversubscribed Series A financing round will be used to drive the lead development program toward clinical proof-of-concept and to broaden the therapeutic value of the proprietary iRhom2 strategy.Munich, Germany, July 9, 2024 –SciRhom GmbH, a biopharmaceutical company pioneering the development of first-in-class therapeutic iRhom2 antibodies, announced today the closing of a EUR 63 million (USD 70 million) Series A financing round. The round was co-led by Andera...
Nasdaq GlobeNewswire
09/07/2024

Roche receives CE Mark for its AI-enabled continuous glucose monitoring solution…

The Accu-Chek® SmartGuide CGM solution provides 14 days of accurate 1real-time glucose values for adults living with type 1 and type 2 diabetes on flexible insulin therapy.The built-in AI-trained algorithms will empower users to proactively intervene when their glucose levels require attention and before a complication can even occur.The solution is set to launch in selected European markets in the coming months.Basel, 09 July 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY)...
Nasdaq GlobeNewswire
09/07/2024

Vivoryon Therapeutics N.V. to Host R&D Update Call on July 18, 2024 Focused on…

Vivoryon Therapeutics N.V. to Host R&D Update Call on July 18, 2024 Focused on Progress in Kidney DiseaseHalle (Saale) / Munich, Germany, July 9, 2024- Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) ( Vivoryon ), a clinical stage company focused on the discovery and development of small molecule medicines to modulate the activity and stability of pathologically altered proteins, today announced that it will host an R&D update conference call and webcast on...
Nasdaq GlobeNewswire
09/07/2024

Io Therapeutics, Inc., announces presentation of data on induction of tumor…

The presented studies showed that oral treatment with IRX5010 resulted in suppression of growth in mouse models of each of five types of the most prevalent and deadly cancers in humans, i.e. triple negative breast, Her-2 positive breast, non-small cell lung, colorectal, and prostate cancers. In all five models, treatment with IRX5010 induced tumor infiltrating effector memory phenotype T-lymphocytes associated with reduction in tumor growth. Treatment with IRX5010 did not directly impact...
Nasdaq GlobeNewswire
09/07/2024

Eli Lilly's Donanemab Approval Heats Up Alzheimer's Disease Treatment Market |…

As per DelveInsight analysis, in 2023, the total diagnosed prevalent cases of Alzheimer's disease in the 7MM were 15.4 million. These cases are projected to increase further during the forecast period (2024–2034). As per DelveInsight analysis, in 2023, the total diagnosed prevalent cases of Alzheimer's disease in the 7MM were15.4 million. These cases are projected to increase further during the forecast period (2024–2034). In 2023,the United Stateshad the highest proportion of...
PR Newswire
08/07/2024

Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF

AMF Regulated InformationMontrouge, France, July 8, 2024 Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today issued the Half-Year report on its liquidity contract with ODDO BHF.Under the liquidity contract between DBV Technologies and ODDO BHF, the following assets appeared on the liquidity account as of June 30, 2024: 303,744 DBV...
Nasdaq GlobeNewswire
08/07/2024

Boehringer Ingelheim produces its own green energy

German Vice Chancellor and Federal Minister of Economics Robert Habeck inaugurates new biomass power plantIngelheim site can cover 95% of its energy needs from renewable sourcesNew power plant helps achieve the company's global climate targets and saves around 50,000 tons of CO 2per year Boehringer Ingelheim inaugurated a biomass power plant at its Ingelheim site on Monday. With the new power plant, Boehringer Ingelheim is optimizing its energy supply and protecting the environment at...
Nasdaq GlobeNewswire
08/07/2024

Oxurion signs a Letter of Intent and enters into exclusive negotiations to…

Oxurion signs a Letter of Intent and enters into exclusive negotiations to potentially acquire a pioneering French CRO in stem cell productionLEUVEN, BELGIUM - July 8, 2024 – 6:30 pm,OxurionNV(Euronext Brussels: OXUR), a biopharmaceutical company based in Leuven, announces that it has signed a Letter of Intent (LOI) to enter into exclusive negotiations with a view to, subject to certain conditions, acquiring an 80% majority stake in a CRO(Contract Research Organisation)...
Nasdaq GlobeNewswire
08/07/2024

Half-year statement of IPSEN liquidity agreement - 2024 06 30

Half-year statement of IPSEN liquidity agreement with NATIXIS ODDO BHF PARIS, FRANCE, July 8, 2024- Under the liquidity agreement entrusted by IPSEN SA to NATIXIS ODDO BHF, as of June 30, 2024, the following resources were included to the dedicated liquidity account: 34,591 shares€1,418,034.45It is reminded that as of the date of the signature of the agreement, the following assets were allocated to the liquidity account: 12,751 shares€3,137,934.80 Between January 1 st,...
Nasdaq GlobeNewswire
08/07/2024

Casino Group: Renewal of partnership with Sherpa

Press release 8 July 2024 The Sherpa Cooperative and Casino renew their partnership to supply 119 Sherpa storesCasino and the Sherpa Cooperative announced today that they have renewed their partnership. Casino will continue to supply the 119 food stores in the Sherpa network, which is the retail benchmark in mountain regions. This renewal is a continuation of the partnership that has linked the two brands since 2009. The supply contract includes providing cooperative members...
Nasdaq GlobeNewswire
08/07/2024

Roche to reintroduce Susvimo in the US for people with neovascular age-related…

The FDA has approved updates to Susvimo, which will be available to US retina specialists and patients with nAMD in the coming weeksSusvimo offers the first alternative to regular eye injections that are standard of care for nAMD, which impacts 20 million people worldwide and can cause blindness if left untreatedBy continuously delivering medicine to the eye through a refillable implant, Susvimo is the first and only approved nAMD treatment shown to maintain vision with two refills a...
Nasdaq GlobeNewswire
08/07/2024

DNA Diagnostics Market Set to Reach USD 21.2 Billion by 2029, Driven by…

Browse in-depth TOC on "DNA Diagnostics Market". Browse in-depth TOC on "DNA Diagnostics Market". 350 - Tables48 - Figures347 - Pages Market Leadership and Strategy Illumina Inc. leads the DNA diagnostics market, leveraging its expertise in sequencing and array-based solutions for genetic analysis. The company's integrated systems, consumables, and informatics platforms support comprehensive genetic analysis and are pivotal in maintaining its market dominance....
PR Newswire
08/07/2024

IVD Reagents Market to be Worth $79.76 Billion by 2031 - Exclusive Report by…

In-vitro diagnostic (IVD) reagents include oligonucleotides, antibodies, nucleic acid probes, purified proteins or peptides, buffers, calibrators, serum, cell medium, and standards & controls used in research activities. These reagents are used to diagnose and prevent diseases or other conditions and manufacture IVD kits & assays for diagnostic purposes. In-vitro diagnostic (IVD) reagents include oligonucleotides, antibodies, nucleic acid probes, purified proteins or peptides…
PR Newswire
08/07/2024
Altri  Comunicati